Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
MammaPrint is the only FDA-cleared gene expression test to identify Read More
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
Demonstrates the ongoing impact of its 10,000-patient FLEX trial to Read More
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- Read More
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
Data show MammaPrint® is the first and most comprehensive FDA-cleared test Read More
Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments
Data demonstrate Research Use Only ImPrint test’s ability to identify Read More
Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer
Company to present multiple recent Registry sub-studies driving cancer care Read More
Budget impact analysis for the Health Care Package by using MammaPrint in Belgium
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure Read More
Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022AuthorsEsther Schuler(1), Sahra Uygun(2), Lorenza Read More
Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More
Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Read More
